Pacira BioSciences to Participate in Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference
Pacira BioSciences (Nasdaq: PCRX), a leading provider of non-opioid pain therapies, has announced its participation in the 24th Annual Needham Virtual Healthcare Conference. The company will engage in an analyst-led fireside chat scheduled for Monday, April 7, 2025, at 11:45 AM ET.
Interested parties can access the live audio stream of the virtual event through the 'Events' section on the company's investor website at investor.pacira.com. A recording of the webcast will remain available for two weeks after the event.
Pacira BioSciences (Nasdaq: PCRX), un fornitore leader di terapie per il dolore non oppioidi, ha annunciato la sua partecipazione alla 24ª Conferenza Virtuale Annuale di Needham sulla Salute. L'azienda parteciperà a una chiacchierata informale guidata da un analista, programmata per lunedì 7 aprile 2025, alle 11:45 AM ET.
Le parti interessate possono accedere allo streaming audio dal vivo dell'evento virtuale attraverso la sezione 'Eventi' sul sito web per investitori dell'azienda all'indirizzo investor.pacira.com. Una registrazione del webcast sarà disponibile per due settimane dopo l'evento.
Pacira BioSciences (Nasdaq: PCRX), un proveedor líder de terapias para el dolor no opioides, ha anunciado su participación en la 24ª Conferencia Virtual Anual de Salud de Needham. La empresa participará en una charla informal dirigida por un analista programada para el lunes 7 de abril de 2025, a las 11:45 AM ET.
Las partes interesadas pueden acceder a la transmisión de audio en vivo del evento virtual a través de la sección 'Eventos' en el sitio web para inversores de la empresa en investor.pacira.com. Una grabación del webcast estará disponible durante dos semanas después del evento.
Pacira BioSciences (Nasdaq: PCRX), 비오피오이드 통증 치료의 선도적인 제공업체가 제24회 니드햄 연례 가상 헬스케어 컨퍼런스에 참여한다고 발표했습니다. 회사는 2025년 4월 7일 월요일, 오전 11시 45분 ET로 예정된 애널리스트 주도의 화상 대화에 참여할 것입니다.
관심 있는 분들은 회사의 투자자 웹사이트의 '이벤트' 섹션을 통해 가상 이벤트의 실시간 오디오 스트림에 접근할 수 있습니다. 웹캐스트 녹화는 이벤트 후 2주 동안 제공됩니다.
Pacira BioSciences (Nasdaq: PCRX), un fournisseur leader de thérapies antidouleur non opioïdes, a annoncé sa participation à la 24ème Conférence Virtuelle Annuelle de Needham sur la Santé. L'entreprise participera à une discussion informelle dirigée par un analyste, prévue pour lundi 7 avril 2025, à 11h45 ET.
Les parties intéressées peuvent accéder au flux audio en direct de l'événement virtuel via la section 'Événements' du site web des investisseurs de l'entreprise à l'adresse investor.pacira.com. Un enregistrement du webcast sera disponible pendant deux semaines après l'événement.
Pacira BioSciences (Nasdaq: PCRX), ein führender Anbieter von nicht-opioiden Schmerztherapien, hat seine Teilnahme an der 24. jährlichen virtuellen Gesundheitskonferenz von Needham angekündigt. Das Unternehmen wird an einem von einem Analysten geleiteten Fireside-Chat teilnehmen, der für Montag, den 7. April 2025, um 11:45 Uhr ET geplant ist.
Interessierte Parteien können den Live-Audio-Stream der virtuellen Veranstaltung über den Bereich 'Veranstaltungen' auf der Investorenseite des Unternehmens unter investor.pacira.com abrufen. Eine Aufzeichnung des Webcasts wird zwei Wochen nach der Veranstaltung verfügbar sein.
- None.
- None.
BRISBANE, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will participate in an analyst-led fireside chat at the 24th Annual Needham Virtual Healthcare Conference at 11:45 AM ET on Monday, April 7, 2025.
Live audio of the virtual event can be accessed by visiting the “Events” page of the company’s website at investor.pacira.com. A replay of the webcast will also be available for two weeks following the event.
About Pacira
Pacira delivers innovative, non-opioid pain therapies to transform the lives of patients. Pacira has three commercial-stage non-opioid treatments: EXPAREL® (bupivacaine liposome injectable suspension), a long-acting local analgesic currently approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block, an adductor canal nerve block, and a sciatic nerve block in the popliteal fossa for postsurgical pain management; ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain; and ioveraº®, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. The company is also advancing the development of PCRX-201, a novel locally administered gene therapy with the potential to treat large prevalent diseases like osteoarthritis. To learn more about Pacira, visit www.pacira.com.
Company Contact: Pacira BioSciences, Inc. Christian Pedetti (973) 254-4387 Christian.pedetti@pacira.com
FAQ
When is Pacira BioSciences (PCRX) presenting at the Needham Healthcare Conference 2025?
How can investors access PCRX's Needham Conference presentation?
What is the format of PCRX's presentation at the Needham Healthcare Conference?
How long will PCRX's Needham Conference presentation recording be available?
